Skip to main content
Samuel Blackman, MD, Pediatric Hematology & Oncology, Seattle, WA

SamuelCharlesBlackmanMDPhD

Pediatric Hematology & Oncology Seattle, WA

Pediatric Neuro-Oncology

Founder and Chief Medical Officer, Day One Biopharmaceuticals, Inc.

Dr. Blackman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Blackman's full profile

Already have an account?

Education & Training

  • Childrens Hospital
    Childrens HospitalFellowship, Pediatric Hematology/Oncology, 2004 - 2008
  • Childrens Hospital
    Childrens HospitalFellowship, Pediatric Hematology/Oncology, 2007
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati Childrens Hospital Medical CenterResidency, Pediatrics, 2004
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati Childrens Hospital Medical CenterInternship, Pediatrics, 2001 - 2002
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoClass of 2001

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2008 - 2022

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study
    Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 StudyNovember 20th, 2020
  • Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib
    Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor PimasertibFebruary 24th, 2021
  • Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-Altered Solid Tumors
    Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-Altered Solid TumorsNovember 25th, 2021
  • Join now to see all

Professional Memberships